The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

AmerisourceBergen establishes Clinical Trial Navigator tool to increase access to research opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

AmerisourceBergen launched Clinical Trial Navigator, a solution suite that supports biopharmaceutical clinical trial recruitment within community-based specialty practices. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 
Sponsored

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
By Jeff Sorenson
Clinical Roundup

Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
Clinical Roundup

OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial

OST-HER2-treated patients showed statistically significant benefit in an interim three-year overall survival data analysis when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the company’s phase IIb trial for the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma (the “Metastatic Osteosarcoma Program”).
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account